Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene

Clin Lung Cancer. 2016 Mar;17(2):e17-21. doi: 10.1016/j.cllc.2015.12.001. Epub 2015 Dec 18.

Authors

Nathaniel J Myall¹, Joel W Neal², Cheryl D Cho-Phan², Lisa Y Zhou², Henning Stehr³, Li Zhou³, Maximilian Diehn³, Heather A Wakelee⁴

Affiliations

¹ Department of Internal Medicine, Stanford Hospital and Clinics, Stanford, CA.
² Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, CA.
³ Department of Radiation Oncology, Stanford Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA.
⁴ Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, CA. Electronic address: hwakelee@stanford.edu.

PMID: 26776917
DOI: 10.1016/j.cllc.2015.12.001

No abstract available

Keywords: Adenocarcinoma; Cancer personalized profiling; Targeted therapy; Vemurafenib.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / genetics*
Aged
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Disease Progression
Erlotinib Hydrochloride / therapeutic use
Humans
Indoles / pharmacology
Indoles / therapeutic use*
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Male
Molecular Targeted Therapy
Mutation / genetics*
Precision Medicine
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
Vemurafenib

Substances

Indoles
Sulfonamides
Vemurafenib
Erlotinib Hydrochloride
BRAF protein, human
Proto-Oncogene Proteins B-raf